EP1097147A4 - Novel angiogenesis inhibitors - Google Patents
Novel angiogenesis inhibitorsInfo
- Publication number
- EP1097147A4 EP1097147A4 EP99937204A EP99937204A EP1097147A4 EP 1097147 A4 EP1097147 A4 EP 1097147A4 EP 99937204 A EP99937204 A EP 99937204A EP 99937204 A EP99937204 A EP 99937204A EP 1097147 A4 EP1097147 A4 EP 1097147A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- angiogenesis inhibitors
- novel angiogenesis
- novel
- inhibitors
- angiogenesis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9228598P | 1998-07-10 | 1998-07-10 | |
| US92285P | 1998-07-10 | ||
| GBGB9822700.2A GB9822700D0 (en) | 1998-10-16 | 1998-10-16 | Novel angiogenesis inhibitors |
| GB9822700 | 1998-10-16 | ||
| PCT/US1999/015200 WO2000002871A1 (en) | 1998-07-10 | 1999-07-06 | Novel angiogenesis inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP1097147A1 EP1097147A1 (en) | 2001-05-09 |
| EP1097147A4 true EP1097147A4 (en) | 2001-11-21 |
Family
ID=26314531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP99937204A Withdrawn EP1097147A4 (en) | 1998-07-10 | 1999-07-06 | Novel angiogenesis inhibitors |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1097147A4 (en) |
| JP (1) | JP2002520324A (en) |
| AU (1) | AU747427B2 (en) |
| CA (1) | CA2336848A1 (en) |
| WO (1) | WO2000002871A1 (en) |
Families Citing this family (119)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| NZ513639A (en) | 1999-04-15 | 2004-02-27 | Bristol Myers Squibb Co | Cyclic protein tyrosine kinase inhibitors |
| DE10021246A1 (en) * | 2000-04-25 | 2001-10-31 | Schering Ag | New N-substituted benzamide derivatives are tyrosine kinase KDR and FLT inhibitors useful e.g. for treating tumors, psoriasis, rheumatoid arthritis, diabetic retinopathy or liver sclerosis |
| AU3113902A (en) | 2000-12-21 | 2002-07-01 | Bristol Myers Squibb Co | Thiazolyl inhibitors of tec family tyrosine kinases |
| ES2556946T3 (en) | 2000-12-21 | 2016-01-21 | Novartis Ag | Pyrimidinamines as angiogenesis modulators |
| US7081454B2 (en) | 2001-03-28 | 2006-07-25 | Bristol-Myers Squibb Co. | Tyrosine kinase inhibitors |
| US6693134B2 (en) | 2001-05-29 | 2004-02-17 | Chemokine Therapeutics Corporation | Bicyclic aromatic chemokine receptor ligands |
| US7265134B2 (en) | 2001-08-17 | 2007-09-04 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| EP1503757B1 (en) | 2002-05-02 | 2007-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| JP4896518B2 (en) * | 2002-12-13 | 2012-03-14 | ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド | Nicotinamide kinase inhibitor |
| NZ544797A (en) | 2003-07-18 | 2011-04-29 | Amgen Fremont Inc | Specific antibodies that bind HGF and neutralise binding of HGF to met |
| US7312215B2 (en) | 2003-07-29 | 2007-12-25 | Bristol-Myers Squibb Company | Benzimidazole C-2 heterocycles as kinase inhibitors |
| ES2611604T3 (en) * | 2004-10-22 | 2017-05-09 | Janssen Pharmaceutica Nv | C fms kinase inhibitors |
| US7652009B2 (en) | 2004-11-30 | 2010-01-26 | Amgem Inc. | Substituted heterocycles and methods of use |
| US20060281788A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
| US20080108664A1 (en) | 2005-12-23 | 2008-05-08 | Liu Belle B | Solid-state form of AMG 706 and pharmaceutical compositions thereof |
| AR059066A1 (en) | 2006-01-27 | 2008-03-12 | Amgen Inc | COMBINATIONS OF THE ANGIOPOYETINE INHIBITOR -2 (ANG2) AND THE VASCULAR ENDOTELIAL GROWTH FACTOR INHIBITOR (VEGF) |
| ATE489380T1 (en) | 2006-02-10 | 2010-12-15 | Amgen Inc | HYDRATE FORMS OF AMG706 |
| US8697716B2 (en) | 2006-04-20 | 2014-04-15 | Janssen Pharmaceutica Nv | Method of inhibiting C-KIT kinase |
| EP2016070B1 (en) | 2006-04-20 | 2016-01-13 | Janssen Pharmaceutica N.V. | Inhibitors of c-fms kinase |
| MX2008013533A (en) | 2006-04-20 | 2009-01-15 | Janssen Pharmaceutica Nv | Heterocyclic compounds as inhibitors of c-fms kinase. |
| PE20080403A1 (en) | 2006-07-14 | 2008-04-25 | Amgen Inc | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| WO2008079291A2 (en) | 2006-12-20 | 2008-07-03 | Amgen Inc. | Substituted heterocycles and methods of use |
| WO2008086014A2 (en) | 2007-01-09 | 2008-07-17 | Amgen Inc. | Bis-aryl amide derivatives useful for the treatment of cancer |
| GB0701426D0 (en) * | 2007-01-25 | 2007-03-07 | Univ Sheffield | Compounds and their use |
| US8314087B2 (en) | 2007-02-16 | 2012-11-20 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and methods of use |
| RS56743B1 (en) | 2007-08-21 | 2018-03-30 | Amgen Inc | Human c-fms antigen binding proteins |
| JO3240B1 (en) | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | Inhibitors of c-fms Kinase |
| US9029411B2 (en) | 2008-01-25 | 2015-05-12 | Millennium Pharmaceuticals, Inc. | Thiophenes and uses thereof |
| EP2107054A1 (en) * | 2008-04-01 | 2009-10-07 | Università Degli Studi Di Milano - Bicocca | Antiproliferative compounds and therapeutic uses thereof |
| US9090601B2 (en) | 2009-01-30 | 2015-07-28 | Millennium Pharmaceuticals, Inc. | Thiazole derivatives |
| US8796314B2 (en) | 2009-01-30 | 2014-08-05 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| US9139589B2 (en) | 2009-01-30 | 2015-09-22 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| WO2011161217A2 (en) | 2010-06-23 | 2011-12-29 | Palacký University in Olomouc | Targeting of vegfr2 |
| WO2012021611A1 (en) | 2010-08-11 | 2012-02-16 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| MA34797B1 (en) | 2010-08-11 | 2014-01-02 | Millennium Pharm Inc | HETEROARYLES AND THEIR USES |
| EP2603216A4 (en) * | 2010-08-11 | 2013-12-18 | Millennium Pharm Inc | Heteroaryls and uses thereof |
| WO2012051410A2 (en) | 2010-10-13 | 2012-04-19 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| DK2937349T3 (en) | 2011-03-23 | 2017-02-20 | Amgen Inc | CONDENSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3 |
| CA2831966C (en) | 2011-05-23 | 2016-07-19 | Merck Patent Gmbh | Thiazole derivatives |
| US9745288B2 (en) | 2011-08-16 | 2017-08-29 | Indiana University Research And Technology Corporation | Compounds and methods for treating cancer by inhibiting the urokinase receptor |
| AR090263A1 (en) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | COMBINED ANTIBODY THERAPY AGAINST HUMAN CSF-1R AND USES OF THE SAME |
| CN104870454B (en) | 2012-08-07 | 2020-03-03 | 詹森药业有限公司 | Process for the preparation of heterocyclic ester derivatives |
| CN107266405A (en) | 2012-08-07 | 2017-10-20 | 詹森药业有限公司 | Method for preparing c fms kinase inhibitors |
| EP2890696A1 (en) | 2012-08-29 | 2015-07-08 | Amgen, Inc. | Quinazolinone compounds and derivatives thereof |
| CN104860885B (en) * | 2014-02-24 | 2017-11-17 | 中国科学院上海药物研究所 | Naphthoyl aminated compounds, preparation method and use |
| AU2016205311B2 (en) | 2015-01-08 | 2022-02-17 | The Board Of Trustees Of The Leland Stanford Junior University | Factors and cells that provide for induction of bone, bone marrow, and cartilage |
| WO2016202935A1 (en) | 2015-06-19 | 2016-12-22 | Bayer Pharma Aktiengesellschaft | Glucose transport inhibitors |
| CA3048217A1 (en) | 2016-12-22 | 2018-06-28 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| ES2905676T3 (en) | 2017-05-22 | 2022-04-11 | Amgen Inc | KRAS G12C inhibitors and methods for their use |
| CN111051306B (en) | 2017-09-08 | 2023-01-03 | 美国安进公司 | Inhibitors of KRAS G12C and methods of use thereof |
| ES2995514T3 (en) | 2018-05-04 | 2025-02-10 | Amgen Inc | Kras g12c inhibitors and methods of using the same |
| MX2020010836A (en) | 2018-05-04 | 2021-01-08 | Amgen Inc | Kras g12c inhibitors and methods of using the same. |
| EP3790886B1 (en) | 2018-05-10 | 2024-06-26 | Amgen Inc. | Kras g12c inhibitors for the treatment of cancer |
| AU2019278998B2 (en) | 2018-06-01 | 2023-11-09 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| MX2020012204A (en) | 2018-06-11 | 2021-03-31 | Amgen Inc | KRAS G12C INHIBITORS TO TREAT CANCER. |
| CA3100390A1 (en) | 2018-06-12 | 2020-03-12 | Amgen Inc. | Kras g12c inhibitors encompassing piperazine ring and use thereof in the treatment of cancer |
| JP7516029B2 (en) | 2018-11-16 | 2024-07-16 | アムジエン・インコーポレーテツド | Improved synthesis of key intermediates for KRAS G12C inhibitor compounds |
| JP7377679B2 (en) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | Combination therapy comprising a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer |
| CA3117222A1 (en) | 2018-11-19 | 2020-05-28 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| WO2020132651A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Kif18a inhibitors |
| PE20211475A1 (en) | 2018-12-20 | 2021-08-05 | Amgen Inc | KIF18A INHIBITORS |
| MX2021007157A (en) | 2018-12-20 | 2021-08-16 | Amgen Inc | Heteroaryl amides useful as kif18a inhibitors. |
| CA3123227A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Heteroaryl amides useful as kif18a inhibitors |
| JP2022522777A (en) | 2019-03-01 | 2022-04-20 | レボリューション メディシンズ インコーポレイテッド | Bicyclic heteroaryl compounds and their use |
| EP3930845A1 (en) | 2019-03-01 | 2022-01-05 | Revolution Medicines, Inc. | Bicyclic heterocyclyl compounds and uses thereof |
| EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
| CN114144414B (en) | 2019-05-21 | 2025-11-07 | 美国安进公司 | Solid state form |
| US12540129B2 (en) | 2019-08-02 | 2026-02-03 | Amgen Inc. | KIF18A inhibitors |
| WO2021026101A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
| CA3147272A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
| CN114302880B (en) | 2019-08-02 | 2025-07-15 | 美国安进公司 | KIF18A inhibitors |
| MX2022004656A (en) | 2019-10-24 | 2022-05-25 | Amgen Inc | PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF KRAS G12C AND KRAS G12D IN THE TREATMENT OF CANCER. |
| CN114867735A (en) | 2019-11-04 | 2022-08-05 | 锐新医药公司 | RAS inhibitors |
| PE20221277A1 (en) | 2019-11-04 | 2022-09-05 | Revolution Medicines Inc | RAS INHIBITORS |
| CN114786777A (en) | 2019-11-04 | 2022-07-22 | 锐新医药公司 | RAS inhibitors |
| PE20230249A1 (en) | 2019-11-08 | 2023-02-07 | Revolution Medicines Inc | BICYCLIC HETEROARYL COMPOUNDS AND THEIR USES |
| TW202132271A (en) | 2019-11-14 | 2021-09-01 | 美商安進公司 | Improved synthesis of kras g12c inhibitor compound |
| CA3158188A1 (en) | 2019-11-14 | 2021-05-20 | Amgen Inc. | Improved synthesis of kras g12c inhibitor compound |
| EP4065231A1 (en) | 2019-11-27 | 2022-10-05 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| CA3163703A1 (en) | 2020-01-07 | 2021-07-15 | Steve Kelsey | Shp2 inhibitor dosing and methods of treating cancer |
| KR20230042600A (en) | 2020-06-18 | 2023-03-28 | 레볼루션 메디슨즈, 인크. | Methods of Delaying, Preventing, and Treating Acquired Resistance to RAS Inhibitors |
| CA3187757A1 (en) | 2020-09-03 | 2022-03-24 | Ethan AHLER | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| AU2021345111B2 (en) | 2020-09-15 | 2025-11-27 | Revolution Medicines, Inc. | Indole derivatives as Ras inhibitors in the treatment of cancer |
| EP4267250A1 (en) | 2020-12-22 | 2023-11-01 | Qilu Regor Therapeutics Inc. | Sos1 inhibitors and uses thereof |
| EP4334324A1 (en) | 2021-05-05 | 2024-03-13 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| CR20230558A (en) | 2021-05-05 | 2024-01-24 | Revolution Medicines Inc | RAS INHIBITORS FOR CANCER TREATMENT |
| AR125782A1 (en) | 2021-05-05 | 2023-08-16 | Revolution Medicines Inc | RAS INHIBITORS |
| AR127308A1 (en) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | RAS INHIBITORS |
| WO2023114954A1 (en) | 2021-12-17 | 2023-06-22 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| IL314883A (en) | 2022-03-07 | 2024-10-01 | Amgen Inc | A process for preparing 4-methyl-2-propan-2-yl-pyridine-3-carbonitrile |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| AU2023285116A1 (en) | 2022-06-10 | 2024-12-19 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| EP4601644A1 (en) | 2022-10-14 | 2025-08-20 | Black Diamond Therapeutics, Inc. | Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| WO2024211663A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| EP4688790A1 (en) | 2023-04-07 | 2026-02-11 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| AU2024252105A1 (en) | 2023-04-14 | 2025-10-16 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| WO2024216016A1 (en) | 2023-04-14 | 2024-10-17 | Revolution Medicines, Inc. | Crystalline forms of a ras inhibitor |
| CN121712509A (en) | 2023-05-04 | 2026-03-20 | 锐新医药公司 | Combination therapy for RAS related diseases or conditions |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| IL327306A (en) | 2023-10-12 | 2026-05-01 | Revolution Medicines Inc | Macrocyclic ras inhibitors |
| WO2025137507A1 (en) | 2023-12-22 | 2025-06-26 | Regor Pharmaceuticals, Inc. | Sos1 inhibitors and uses thereof |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5104889A (en) * | 1986-08-04 | 1992-04-14 | Otsuka Pharmaceutical Factory, Inc. | Thiazole derivatives |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1497536A (en) * | 1973-12-17 | 1978-01-12 | Lilly Industries Ltd | 2-acylaminooxazoles methods for their preparation and their use |
| DE3864248D1 (en) * | 1987-12-14 | 1991-09-19 | Sawai Seiyaku Kk | CARBOXAMIDES WITH TETRAZOLE AND THIAZOLE RINGS AND THEIR USE. |
-
1999
- 1999-07-06 CA CA002336848A patent/CA2336848A1/en not_active Abandoned
- 1999-07-06 WO PCT/US1999/015200 patent/WO2000002871A1/en not_active Ceased
- 1999-07-06 AU AU52082/99A patent/AU747427B2/en not_active Ceased
- 1999-07-06 EP EP99937204A patent/EP1097147A4/en not_active Withdrawn
- 1999-07-06 JP JP2000559102A patent/JP2002520324A/en not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5104889A (en) * | 1986-08-04 | 1992-04-14 | Otsuka Pharmaceutical Factory, Inc. | Thiazole derivatives |
Non-Patent Citations (5)
| Title |
|---|
| CHEM. HETEROCYCL. COMPD. (ENGL. TRANSL.) (1974), 10(7), 928-931 * |
| DATABASE BEILSTEIN [online] BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT/MAIN, DE; XP002176558, Database accession no. 998965 (BRN) * |
| DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002176557, retrieved from STN Database accession no. 75:35847 * |
| See also references of WO0002871A1 * |
| YAKUGAKU ZASSHI (1971), 91(4), 436-443 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU5208299A (en) | 2000-02-01 |
| AU747427B2 (en) | 2002-05-16 |
| CA2336848A1 (en) | 2000-01-20 |
| JP2002520324A (en) | 2002-07-09 |
| WO2000002871A1 (en) | 2000-01-20 |
| EP1097147A1 (en) | 2001-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB9900416D0 (en) | Inhibitors | |
| PL341642A1 (en) | Novel macrolydes | |
| ZA98376B (en) | Sulfamide-metalloprotease inhibitors | |
| GB2321641B (en) | Sulfamide-metalloprotease inhibitors | |
| HUP0202076A3 (en) | Triazine angiogenesis inhibitors | |
| EP1068213A4 (en) | Novel aminoorganofunctionalsiloxanes | |
| PL345574A1 (en) | Angiogenesis inhibitors | |
| GB9821993D0 (en) | Centraliser | |
| EP1153022A4 (en) | Prothease inhibitors | |
| GB9816729D0 (en) | Substituted cyclohexylaminopyrimidines | |
| PL347397A1 (en) | Substituted 3-aryl-pyrazoles | |
| GB9817029D0 (en) | Novel compounds | |
| GB2389113B (en) | B-secretase inhibitor | |
| HUP0103576A3 (en) | Kdel receptor inhibitors | |
| HUP0102476A3 (en) | Substituted cyclooctadepsipeptides | |
| GB9810544D0 (en) | Novel angiogenesis inhibitors | |
| GB9822700D0 (en) | Novel angiogenesis inhibitors | |
| GB9800681D0 (en) | Novel angiogenesis inhibitors | |
| TW407677U (en) | Form | |
| GB9803416D0 (en) | Inhibitors | |
| GB9828697D0 (en) | Inhibitors | |
| GB9826992D0 (en) | Inhibitors | |
| ZA9811227B (en) | Triazine angiogenesis inhibitors | |
| SI1037886T1 (en) | Triazine angiogenesis inhibitors | |
| GB9825756D0 (en) | Novel compoundd |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20010212 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
| AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
| RIC1 | Information provided on ipc code assigned before grant |
Free format text: 7C 07D 263/48 A, 7C 07D 277/46 B, 7A 61K 31/42 B, 7A 61K 31/425 B, 7C 07D 413/04 B, 7C 07D 413/14 B |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20011005 |
|
| AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
| 17Q | First examination report despatched |
Effective date: 20030918 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20040330 |